| Program | Modality | Target | Indication | Stage |
|---|---|---|---|---|
| AlphaPARP | Alpha Therapy (²¹¹At) | PARP1 | Ovarian Cancer, relapsed/refractory | IND-Enabling |
| Prostate Cancer (mCRPC) | Preclinical | |||
| Breast Cancer (TNBC) | Preclinical | |||
| Neuroblastoma | Preclinical (Strong POC) | |||
| Pancreatic Cancer | Exploratory | |||
| Small Cell Lung Cancer | Exploratory | |||
| PARPTrace | PET Diagnostic (¹⁸F) | PARP1 | Multiple tumor types, completing Phase 2 multi-center breast cancer trial | 300+ patients imaged |
PARP1 is expressed across major solid tumor populations. The addressable market grows as the program advances through the indication ladder.
| Indication | Initial Target | Ultimate Target |
|---|---|---|
| Ovarian | PARPi-Resistant (~$1B) | Stage 3/4 with PARP1 binding (~$2B) |
| Prostate | mCRPC (~$7B) | Same as Initial target |
| Breast | Triple-Negative (~$4B) | TNBC + ER+/HER- with PARP1 binding (~$12B) |
U.S. total addressable market figures from the current investor pitch model.
Trevarx is currently completing IND-enabling work and CMC readiness for early clinical development. IND submission is targeted for early 2027 as a Trevarx IND to be conducted by University of Pennsylvania. First-in-human dosimetry studies are projected to begin in 2027 and Phase 1 dose escalation and expansion in relapsed/refractory ovarian cancer following.
The detailed development plan, milestone gates, and financing structure are reserved for the investor conversation. Use the contact form to request a briefing.
(Based on public pipeline mapping)
Trevarx is the only identified IND-enabling targeted alpha program built for DNA-directed intranuclear delivery.
Most other named programs in development or approval focus on cell-surface, extracellular, or non-DNA-localized delivery.
The major alpha RLT acquirees and later-stage competitors largely compete on molecular target.
AlphaPARP reframes the competitive axis around delivery geometry: where the radiation fires relative to tumor DNA.
AlphaPARP uses Astatine-211, well matched to the small-molecule PARP-targeting scaffold.
Supply chain remains a known execution variable across the alpha RLT field, but Trevarx has a staged plan for early clinical supply, CMC development, and later network scale-up.
